Dow Jones Update: Stock Futures Dip on Inflation Report, Bank Earnings Surge; Gold & Silver Hit All-Time Highs

Stock futures slipped Wednesday as investors reacted to wholesale inflation data and fresh bank earnings, while safe-haven assets surged. Gold and silver set new record highs, underscoring investor demand for stability amid market volatility.

Nasdaq 100, S&P 500, and Dow Jones futures fell 0.6%, 0.4%, and 0.3% respectively after the Bureau of Labor Statistics’ delayed Producer Price Index showed wholesale prices rising 0.2% in November, slightly below the 0.3% forecast.

The 10-year Treasury yield held near 4.16% following the inflation report and stronger-than-expected retail sales, which rose 0.6% versus a 0.4% estimate.

Major indexes closed lower Tuesday, with the Dow dropping 400 points as investors digested consumer inflation data and mixed earnings from JPMorgan Chase, whose shares fell over 4% and slipped another 0.5% in premarket trading.

Bank of America and Wells Fargo shares dropped 1.7% and 2.5%, while Citigroup gained 2% after reporting results.

Gold futures hit $4,650 per ounce and silver crossed $90 for the first time, with recent trading showing gold at $4,645 and silver at $91.20 after briefly touching $92.20.

Financial stocks declined again after President Trump suggested capping credit card interest rates at 10%. Visa and Mastercard fell sharply Tuesday but edged higher in premarket trading Wednesday.

Nvidia shares dipped less than 1% after U.S. approval to export its H200 AI chips to China, contingent on new security requirements.

Netflix rose 1.5% on reports of a $72 billion all-cash bid for Warner Bros. Discovery’s HBO Max and studios, while Paramount Skydance countered with a $77.9 billion hostile offer. Paramount shares slipped slightly.

West Texas Intermediate crude rose under 1% to $61.60 per barrel.

TG Therapeutics (TGTX) shares surged 10% in premarket trading Wednesday after the biopharma company raised its full-year revenue outlook during the 44th Annual J.P. Morgan Healthcare Conference.

The New York-based firm now expects fiscal 2025 revenue of $616 million, up from $600 million, with sales of its multiple sclerosis treatment Briumvi projected at $594 million versus prior guidance of $585 million. Both figures topped Visible Alpha consensus forecasts.

CEO Michael Weiss highlighted Briumvi’s strong commercial momentum in 2025, reinforcing confidence in its multi-billion-dollar market potential.

For 2026, TG Therapeutics projects revenue between $875 million and $900 million, including U.S. Briumvi net product revenue of $825 million to $850 million. The Briumvi forecast exceeded Visible Alpha estimates, while total revenue guidance aligned with expectations.

Despite the recent surge, TG Therapeutics shares remain down 6% over the past year.

Stock futures weakened as inflation data and mixed bank earnings weighed on investor sentiment, while safe-haven assets surged. Gold and silver hit fresh record highs, underscoring demand for stability. Financial stocks faced pressure from policy talk on credit card rates, Nvidia slipped on new export rules, and Netflix advanced on its Warner Bros. bid. Oil edged higher, Bitcoin hovered near $95,000, and the dollar eased slightly painting a picture of cautious markets balancing risk with opportunity.